Lean Hogs (LH)

Labcorp Holdings에 대한 매도 수량은 투자자에게 Labcorp Holdings의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Labcorp Holdings (NYSE:LH) 주식, 공매도 수량 보고

Labcorp Holdings

Laboratory Corp

Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.

News

Movers

ALNY

CHRW

COKE

CVNA

DASH

DXCM

EXAS

Laboratory Corporation Of America Holdings

PYPL

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 이그젝트 사이언스(NASDAQ:EXAS)가 예상보다 나은 2분기 재무 결과를 보고하고 트윈스트랜드 바이오사이언스(TwinStrand Biosciences)와 독점 라이센스 계약을 발표한 후 주가는 26.60% 상승했다. 몇몇 분석가들은 주식에 대한 가격 예측을 하향 조정했다.

도어대시와 이그젝트 사이언스는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (7월 28일-8월 3일)

Labcorp Holdings Inc

Linkhome Holdings Inc

Leo Holdings Corp II Warrants (07/01/2028)

Lucira Health Inc Ordinary Shares

LIC HSG FIN S/GDR 144A by Lic Housing Finance Ltd.

LIGHTHOUSE GLOGAL HLDGS by Lighthouse Global Holdings Inc.

Lighthouse Global Holdings Inc

LEHMAN BRO HLDC/T 6.00% M by Lehman Brothers Holdings, Inc.

Lehman Brothers Holdings Capital Trust V

LEADER HILL CORP by Leader Hill Corp.

LIFEHOUSE RETIREMENT PPTY by LifeHouse Retirement Properties, Inc.

LIGHTSTONE VALUE REIT by Lightstone Value Plus REIT Inc.

Lightstone Value Plus REIT I Inc

LIANHUA SUPERMKT HLDGS CO by Lianhua Supermarket Holdings Ltd.

Lianhua Supermarket Holdings Co Ltd

LIANHUA SPRMKT UNSP/ADR by Lianhua Supermarket Holdings Ltd.

L3Harris Technologies Inc

Lhyfe SA

On Wednesday, Donald Trump, the Republican candidate and former president, was elected to the highest office again, marking a return to an administration. His second term is likely to impact U.S. healthcare.
Trump has been unclear about his healthcare policy goals during his campaign. Healthcare <a target="_blank" href="https://www.kff.org/health-care-in-2024-elections-apvotecast-polling/?entry=kff-analysis-of-ap-votecast-abortion-ballot-initiatives" rel="noreferrer noopener">ranked</a> lower than issues like the economy and immigration in voter concerns.
A <a target="_blank" href="https://apnews.com/article/ap-votecast-elections-harris-trump-voters-d5cf4e3611f50ec4349d93ddc7f037cd" rel="noreferrer noopener">poll</a> from the Associated Press found that only 8% of voters viewed healthcare as their top issue, compared to 39% who chose the economy and 20% who picked immigration. Abortion was the leading issue for 11% of voters.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction" rel="noreferrer noopener">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a>
Despite his focus on &#8220;Make America Healthy Again,&#8221; millions of Americans may lose health insurance subsidies next year, depending on the political climate after the election and the Republicans&#8217; control of the Senate.
The subsidies, expanded under the 2021 American Rescue Plan, help many, particularly the middle class, afford health insurance through the Affordable Care Act (ACA).
These subsidies are set to expire at the end of 2025, and it remains uncertain whether they will be extended under the new administration.
Trump and other Republicans have opposed continuing the subsidies.
The NBC News <a target="_blank" href="https://www.nbcnews.com/health/health-news/millions-risk-losing-health-insurance-trumps-victory-rcna179146" rel="noreferrer noopener">report</a>, citing some analysts, suggests that the chances of extension could be less than 5% if Republicans win control of the House and the Senate.
Even if Democrats control the House, extending these subsidies seems unlikely. Without an extension, nearly 4 million Americans could lose coverage by 2026 due to unaffordable premiums.
The 2021 changes led to a surge in ACA enrollment, with 15.5 million people benefiting from subsidies across 32 states. The report adds that if the subsidies aren&#8217;t renewed, up to 15.4 million Americans could lose health coverage by 2030.
Another significant issue is Trump&#8217;s stance on Medicare. As president, he supported Medicare Advantage, a private insurer-run program that could eventually replace traditional, government-run Medicare.
The NPR report <a target="_blank" href="https://www.npr.org/sections/shots-health-news/2024/11/07/nx-s1-5183092/trump-election-2024-medicare-advantage" rel="noreferrer noopener">highlights</a> that critics argue that expanding private insurers could increase costs for taxpayers and limit care, with some beneficiaries finding it difficult to switch back to traditional Medicare.
Robert Berenson, a former government official, warned that traditional Medicare could &#8220;wither on the vine.&#8221;
Medicare Advantage grew with the 2003 legislation introducing a drug benefit and expanded private insurers&#8217; role in the program. Although private plans were expected to lower costs, they have been more expensive.
The report also says that in 2023, Medicare Advantage plans cost taxpayers about 6% — or $27 billion — more than traditional Medicare, though some research suggests they offer better care.
The future of healthcare policy in the U.S. will depend on the political dynamics in Congress and Trump&#8217;s second term.
With Republicans pushing for major changes to the ACA and Medicare, experts warn of significant shifts in how Americans access and pay for healthcare in the coming years.
Read Next
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41855578/bristol-myers-squibb-leads-biopharma-recovery-with-almost-25-growth-in-market-cap-but-novo-nordisk-and-lilly-suffer-market-setbacks" target="_blank" rel="noreferrer noopener">Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks</a></li>
</ul>
Photo via Shutterstock

Government

Regulations

Health Care

Politics

Markets

General

ALHC

CLOV

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare

HSBC analyst Morten Herholdt upgrades Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) from Hold to Buy.

Upgrades

Analyst Ratings

HSBC Upgrades Labcorp Holdings to Buy

Piper Sandler analyst David Westenberg maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Neutral and raises the price target from $235 to $240.

Price Target

Piper Sandler Maintains Neutral on Labcorp Holdings, Raises Price Target to $240

Barclays analyst Jack Meehan maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Equal-Weight and raises the price target from $234 to $249.

Barclays Maintains Equal-Weight on Labcorp Holdings, Raises Price Target to $249

Across the recent three months, 12 analysts have shared their insights on Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $258.83, a high estimate of $289.00, and a low estimate of $230.00. Witnessing a positive shift, the current average has risen by 3.42% from the previous average price target of $250.27.
<img src="https://www.benzinga.com/files/images/story/2024/1729864848_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Labcorp Holdings is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$289.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$234.00</td>
<td>$249.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Neutral</td>
<td>$235.00</td>
<td>-</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$240.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$265.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$282.00</td>
<td>$278.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$270.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$249.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$277.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$255.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Labcorp Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Labcorp Holdings compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Labcorp Holdings's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Labcorp Holdings's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Labcorp Holdings analyst ratings.</a>
<h2>About Labcorp Holdings</h2>
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Labcorp Holdings's Financial Performance</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Labcorp Holdings's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 6.17%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Labcorp Holdings's net margin excels beyond industry benchmarks, reaching 6.37%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Labcorp Holdings's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.57% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.24%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.75.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Labcorp Holdings Through The Eyes Of 12 Analysts

Baird analyst Eric Coldwell maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Outperform and raises the price target from $282 to $289.

Baird Maintains Outperform on Labcorp Holdings, Raises Price Target to $289

Thursday, Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) reported third-quarter 2024 adjusted earnings per share of $3.50, up from $3.38 a year ago, beating <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">the consensus of $3.49</a>.
Sales increased 7.4% year-over-year to $3.28 billion, almost in line with the consensus of $3.26 billion.
The increase was due to organic revenue of 4.2%, acquisitions, net of divestitures of 3.1%, and foreign <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41512196/labcorp-announces-2024-third-quarter-results" rel="noreferrer noopener">currency translation of 0.1%</a>.
The 4.2% increase in organic revenue was driven by a 4.8% increase in the company's organic Base Business, partially offset by a (0.6%) decrease in COVID-19 testing.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/08/40559658/diagnostic-giants-labcorp-roche-to-ramp-up-testing-capacity-amid-global-concerns-over-new-mpox-str" rel="noreferrer noopener">Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain</a>
Adjusted operating income for the quarter was&nbsp;$441.1&nbsp;million, or 13.4% of revenue, compared to&nbsp;$423.9 million, or 13.9%, in the third quarter of 2023.
William Blair reported that the operating margin came in about 30 basis points below expectations, primarily due to a lower margin in the diagnostics segment, which stood at 15.2%. This decline was influenced by fewer operational days caused by adverse weather and <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38442059/labcorps-q1-revenue-surpasses-forecasts-analysts-scrutinize-invitae-deal" rel="noreferrer noopener">dilution from Invitae</a>.
Diagnostics Laboratories revenue for the quarter was&nbsp;$2.55 billion, an increase of 8.9%.
Biopharma Laboratory Services revenue increased 2.6% to $737.7 million.
Guidance:&nbsp;LabCorp expects 2024 adjusted EPS of $14.30-$14.70, compared to <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40109789/labcorps-stock-soars-after-q2-performance-analyst-highlights-strong-position-in-hea" rel="noreferrer noopener">prior guidance of $14.30-$14.90</a> and the consensus of $14.56.
The analyst notes that adjusted EPS guidance was lowered due to a $0.15 headwind from adverse weather impacts and offset by slightly better underlying trends.
The weather impact was slightly greater than expected, but William Blair believes investors will likely overlook this factor, as they did with Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41458004/quest-diagnostics-ceo-touts-new-customer-wins-in-q3-expects-earnings-growth-in-2025" rel="noreferrer noopener">earlier in the week</a>.
The analyst noted that LabCorp could experience a more significant effect from the weather this quarter, given its higher exposure to North Carolina, which was impacted by Hurricane Helene, compared to Quest.
The company expects 2024 revenue growth of 6.6%-7.3%, compared to the prior guidance range of 6.4%-7.5% and the consensus of 12.96 billion.
The guidance includes 2024 Diagnostics Laboratories sales growth of 7.2%-7.8% and Biopharma Laboratory Services&nbsp;sales growth of 4.7%-5.6% versus prior guidance of 6.9%-7.9% and 3.7%-5.0%, respectively.
Price Action: Laboratory stock is up 6.37% at $233.91 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41517795/harley-davidson-q3-earnings-sales-drop-26-high-interest-rates-hit-motorcycle-demand-and-margins-low" target="_blank" rel="noreferrer noopener">Harley-Davidson Q3 Earnings: Sales Drop 26%, High Interest Rates Hit Motorcycle Demand And Margins, Lowers 2024 Outlook</a></li>
</ul>

Analyst Color

Earnings

Large Cap

Guidance

Trading Ideas

Laboratory Corp Q3 Earnings Beat Street View, Investors Overlook Hurricane Helene Impact

U.S. stocks were mixed, with the Nasdaq Composite gaining around 100 points on Thursday.
Shares of United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) rose during Thursday's session after the company reported <a href="https://www.benzinga.com/news/earnings/24/10/41515619/delivery-giant-ups-breaks-revenue-miss-streak-after-10-quarters-stock-soars">better-than-expected quarterly EPS and sales.</a>
UPS reported consolidated revenue growth of 5.6% year-over-year to $22.2 billion, beating the consensus of $22.14 billion. Adjusted EPS was $1.76, up 12.1% YoY, above the consensus of $1.63.
United Parcel Service shares jumped 5% to $137.93 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) shares jumped 31.6% to $6.82 after the company said it has begun producing low volumes of its first B-sample cells and has begun shipping cells for automotive customer testing.</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) gained 22.8% to $337.89 after the company reported better-than-expected third-quarter financial results.</li>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) climbed 20.7% to $345.82 after the company reported better-than-expected third-quarter financial results and raised its FY24 guidance above estimates. Also, the company increased its fourth-quarter dividend.</li>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) gained 18.7% to $71.65 after the company reported better-than-expected third-quarter EPS results.</li>
<li>LendingClub Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) gained 17.7% to $14.67 after the company reported better-than-expected third-quarter financial results.</li>
<li>American Coastal Insurance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) surged 16.8% to $12.09 after the company provided updates on hurricane loss amounts and announced it expects a positive net income for the third quarter.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 16.5% to $248.93 following better-than-expected quarterly earnings.</li>
<li>Celestica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) climbed 15.6% to $66.48 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter revenue guidance above estimates.</li>
<li>Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) gained 15.2% to $33.33 after the company presented data from its ongoing Phase 1a/1b study of ZL-1310 for previously treated extensive-stage small cell lung cancer at the EORTC-NCI-AACR Symposium 2024.</li>
<li>Pegasystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) gained 14.2% to $79.66.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) surged 13.2% to $29.72 after the company announced it bagged a contract with the Space Development Agency as the prime contractor to the US Government.</li>
<li>ADT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>) gained 11.2% to $7.70 after the company reported better-than-expected third-quarter financial results and issued FY24 adjusted EPS above estimates.</li>
<li>Whirlpool Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) rose 10% to $109.18 following a third-quarter EPS beat and guidance above consensus estimates.</li>
<li>Plexus Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) rose 9.9% to $149.00 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gained 9.9% to $12.00 after Keybanc maintained an Overweight rating on the stock and raised its price target from $11 to $12.</li>
<li>CBRE Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NASDAQ">CBRE</a>) gained 9.7% to $135.12 after the company reported better-than-expected third-quarter financial results and raised its FY24 adjusted EPS guidance above estimates.</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) rose 8.2% to $629.72 following upbeat quarterly earnings.</li>
<li>Labcorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) gained 7.6% to $236.52 following strong quarterly earnings.</li>
<li>Pool Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>) gained 7.5% to $377.11 following strong quarterly sales.</li>
<li>T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) gained 4.1% to $230.00 after the company reported better-than-expected third-quarter financial results and raised its FY24 guidance.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41516316/jim-cramer-says-he-would-not-buy-this-health-care-stock-at-this-level-wait-for-a-pullbac">Jim Cramer Says He Would Not Buy This Health Care Stock At This Level: &#8216;Wait For A Pullback&#8217;</a></li>
</ul>

Intraday Update

ACIC

ASTS

CBRE

PEGA

PLXS

POOL

RKLB

TMUS

TSLA

VKTX

ZLAB

UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday

WIIM

Labcorp Holdings shares are trading higher after the company reported better-than-expected Q3 financial results.

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">Previous</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">Updated</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Results</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">2024 Guidance</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">2024 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2023</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1">High</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Labcorp Enterprise (1)(2)</td>
<td colspan="1" rowspan="1">$12.2</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">6.4&nbsp;%</td>
<td colspan="1" rowspan="1">7.5&nbsp;%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">6.6&nbsp;%</td>
<td colspan="1" rowspan="1">7.3&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diagnostics Laboratories</td>
<td colspan="1" rowspan="1">$9.4</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">6.9&nbsp;%</td>
<td colspan="1" rowspan="1">7.9&nbsp;%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">7.2&nbsp;%</td>
<td colspan="1" rowspan="1">7.8&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Biopharma Laboratory Services (3)</td>
<td colspan="1" rowspan="1">$2.8</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">3.7&nbsp;%</td>
<td colspan="1" rowspan="1">5.0&nbsp;%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">4.7&nbsp;%</td>
<td colspan="1" rowspan="1">5.6&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS</td>
<td colspan="1" rowspan="1">$13.56</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$14.30</td>
<td colspan="1" rowspan="1">$14.90</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$14.30</td>
<td colspan="1" rowspan="1">$14.70</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow from Cont. Ops(4)</td>
<td colspan="1" rowspan="1">$0.89</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$0.85</td>
<td colspan="1" rowspan="1">$1.00</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$0.85</td>
<td colspan="1" rowspan="1">$0.98</td>
</tr>
</tbody>
</table>
</figure>

Labcorp Expects 2024 Adjusted EPS Of $14.30-$14.70 Versus Prior Guidance Of $14.30-$14.90 And Consensus Of $14.56

Laboratory Corp Q3 2024 Adj. EPS $3.50 Beats $3.49 Estimate, Sales $3.282B Beat $3.260B Estimate

Barclays analyst Jack Meehan maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Equal-Weight and lowers the price target from $249 to $234.

Barclays Maintains Equal-Weight on Labcorp Holdings, Lowers Price Target to $234

NOWDiagnostics Partners With Labcorp To Expand Access To First FDA-Authorized OTC Syphilis Test In The U.S.; First To Know Syphilis Test To Be Available In Clinical And Hospital Settings By Late 2024, With Direct Patient Access Via Labcorp OnDemand In 2025

Labcorp to serve as the exclusive NOWDiagnostics (NOWDx) distributor for clinical testing in the U.S., offering First to Know&#xAE; Syphilis Test nationwide
BURLINGTON, N.C., Oct 10, 2024 /PRNewswire/ -- Labcorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), a global leader of innovative and comprehensive laboratory services, announced today it has expanded its portfolio of sexually transmitted infection (STI) testing options to include the First to Know&#xAE; Syphilis Test, the first over-the-counter blood test granted market authorization by the U.S. Food &amp; Drug Administration (FDA) that can be performed by both physicians and patients.

Biotech

Labcorp Expands STI Test Offerings, To Serve As The Exclusive NOWDiagnostics Distributor For Clinical Testing In The U.S., Offering First To Know Syphilis Test Nationwide

Labcorp Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lh#NYSE">LH</a>) or Labcorp benefits from the solid execution of its strategic priorities. Investment in targeted high-growth areas should drive the momentum. The company faces headwinds from macroeconomic uncertainties and growing foreign exchange issues. The stock carries a Zacks Rank #3 (Hold) currently.
<h2>Factors Driving LH Stock</h2>
LabCorp is well-placed for long-term success in Cell &amp; Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business. In June 2024, Labcorp Tissue Complete comprehensive genomic profiling (CGP) service was availed in Geneva and Shanghai to support global clinical trials. The integration of OmniSeq INSIGHT circulating tumor DNA expanded Labcorp&#39;s leadership in liquid biopsy comprehensive genomic profiling for solid tumors.
LabCorp&#39;s Biopharma business is benefiting from collaborations with leading pharmaceutical and biotechnology companies with whom it started to work on potential antivirals, treatments and vaccines. Revenue-wise, Biopharma&#39;s growth continues to be driven by strength in central laboratories, its largest part, which improved by 9% in the second quarter of 2024. The Early Development business is also recovering sequentially, led by reduced cancellations and booking improvement, and is expected to generate higher revenues in the second half of the year.
Labcorp has been focused on expanding its margins though the LaunchPad initiative. The company&#39;s 2024-2026 guidance includes a savings target range of $100 million-$125 million annually. The benefits will be driven by rationalizing the geographic location of facilities and talent, leveraging technological advancements and structural enhancements, integrating acquisitions and re-engineering the company&#39;s systems and processes. In the second quarter, the rise in operating income and margin was fueled by the strong demand and LaunchPad savings.
The stock has risen 11.1% in the past three months against the industry&#39;s 2.7% decline. With the company strategically expanding in the high-growth areas, as well as putting focus on cost saving initiatives, we expect the stock to continue its upward movement in the coming days.
<div class="chart_embed">
<h2>Labcorp Price</h2>
<img alt="Labcorp Price" src="https://staticx-tuner.zacks.com/images/charts/6d/1728307858.png" style="height:251px; width:545px" title="" />
Labcorp price | Labcorp Quote
</div>
<h2>Factors Weighing on LH Stock</h2>
Labcorp&#39;s operation is heavily dependent on the demand for diagnostic testing and drug development services from patients, physicians, hospitals, medical device companies and others. Volatilities in global economic conditions, including inflation and the risk of short or long-term recessions, could reduce the demand for these services, affecting the customers&#39; ability to pay and, consequently, the profitability of the company.
Added to this, the escalation of the present geopolitical situations in Ukraine and the Middle East can potentially decrease testing volumes, cause disruptions in the supply chain and services and increase the prices of offerings. In the second quarter, the cost of revenues went up by 4.7% year over year. SG&amp;A expenses increased 10.3%, mainly from higher personnel costs.
Labcorp&#39;s huge exposure in international markets makes it vulnerable to currency fluctuations. In 2023, the BLS segment derived nearly 58% of its revenues from overseas, while Dx also earned a modest portion in Canada and a relatively small amount in the rest of the world. An approximate 13.7% of the company&#39;s revenues were denominated in currencies other than the U.S. dollar in the first half of 2024. With the recent upward trend observed in the value of the U.S. dollar, further acceleration expected by analysts in this value will cause the company&#39;s revenues to face a tough situation overseas.&nbsp;In the second quarter, BLS and Dx revenue growth was partially offset by unfavorable foreign currency translation of 0.1%.
<h2>Key Picks</h2>
Some better-ranked stocks in the broader medical space are Intuitive Surgical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), TransMedics Group&nbsp;and Quest Diagnostics. While Intuitive Surgical and TransMedics currently sport a Zacks Rank #1 (Strong Buy) each, Quest Diagnostics carries a Zacks Rank #2 (Buy).
Intuitive Surgical&#39;s shares have surged 60.5% in the past year. Estimates for the company&#39;s earnings have moved 5.1% north to $1.65 per share for 2024 in the past 30 days.
ISRG&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.
Estimates for TransMedics&#39; 2024 EPS have moved up 125% to 27 cents in the past 30 days. Shares of the company have soared 135.2% in the past year compared with the industry&#39;s 14.9% growth.
TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.
Estimates for Boston Scientific&#39;s 2024 EPS have increased 1.7% to $2.40 in the past 30 days. In the past year, shares of BSX have risen 55.5% compared with the industry&#39;s 17.9% growth.
In the last reported quarter, BSX delivered an earnings surprise of 6.90%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.18%.
<a href="https://www.zacks.com/stock/news/2347044/labcorp-stock-gains-from-biopharma-business-amid-fx-woe?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2347044">To read this article on Zacks.com click here.</a>

Earnings Beats

Macro Economic Events

Offerings

Economics

ISRG

Labcorp Stock Gains From Biopharma Business Amid FX Woe

Piper Sandler analyst David Westenberg initiates coverage on Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Neutral rating and announces Price Target of $235.

Initiation

Piper Sandler Initiates Coverage On Labcorp Holdings with Neutral Rating, Announces Price Target of $235

Evercore ISI Group analyst Elizabeth Anderson maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a In-Line and lowers the price target from $250 to $240.

Evercore ISI Group Maintains In-Line on Labcorp Holdings, Lowers Price Target to $240

Jefferies analyst Brian Tanquilut maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy and raises the price target from $245 to $265.

Jefferies Maintains Buy on Labcorp Holdings, Raises Price Target to $265

Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $257.67, with a high estimate of $282.00 and a low estimate of $215.00. Marking an increase of 5.65%, the current average surpasses the previous average price target of $243.89. 
<img src="https://www.benzinga.com/files/images/story/2024/1726833681_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Labcorp Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$282.00</td>
<td>$278.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$270.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$249.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$277.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$215.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$261.00</td>
<td>$258.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Labcorp Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Labcorp Holdings compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Labcorp Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Labcorp Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Labcorp Holdings analyst ratings.</a>
<h2>Unveiling the Story Behind Labcorp Holdings</h2>
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Labcorp Holdings's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Labcorp Holdings showcased positive performance, achieving a revenue growth rate of 6.17% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.37%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.57%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Labcorp Holdings's ROA excels beyond industry benchmarks, reaching 1.24%. This signifies efficient management of assets and strong financial health.
Debt Management: Labcorp Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.75.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Labcorp Holdings

Baird analyst Eric Coldwell maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Outperform and raises the price target from $278 to $282.

Baird Maintains Outperform on Labcorp Holdings, Raises Price Target to $282

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Laboratory (LH – Research Report), Dexcom (DXCM – Re...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Baird raised the firm's price target on Labcorp (LH) to $289 from $282 and keeps an Outperform rating on the shares. The firm said they posted a st...

Labcorp price target raised to $289 from $282 at Baird

In a report released today, Elizabeth Anderson CFA from Evercore ISI maintained a Hold rating on Laboratory (LH – Research Report), with a price ta...

Evercore ISI Sticks to Its Hold Rating for Laboratory (LH)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Universal Health (UHS – Research Report), Zai Lab (Z...

Analysts' Top Healthcare Picks: Universal Health (UHS), Zai Lab (ZLAB)

Medpace: Buy The Short-Term Pain For Long-Term Gains

Piper Sandler analyst David Westenberg maintained a Hold rating on Laboratory (LH – Research Report) today and set a price target of $240.00. The c...

Laboratory (LH) Receives a Hold from Piper Sandler

Piper Sandler analyst David Westenberg raised the firm's price target on Labcorp (LH) to $240 from $235 following quarterly results. The firm remai...

Labcorp price target raised to $240 from $235 at Piper Sandler

HSBC analyst Sidharth Sahoo upgraded Labcorp (LH) to Buy from Hold. Published first on TheFly – the ultimate source for real-time, market-moving br...

Labcorp upgraded to Buy from Hold at HSBC

First mpox case linked to African outbreak reported in U.K.

Analyst Michael Cherny of Leerink Partners reiterated a Buy rating on Laboratory (LH – Research Report), retaining the price target of $268.00. Mic...

Laboratory's Positive Growth Trajectory and Strategic Acquisitions Justify Buy Rating

APDN

BVNKF

BVNRY

CMRX

CODX

GOVX

ITGR

MEDP

RHHBY

SIGA

TNXP

Press Releases

LABCORP PRICES $650,000,000 IN 4.350% SENIOR NOTES DUE 2030, $500,000,000 IN 4.550% SENIOR NOTES DUE 2032 AND $850,000,000 IN 4.800% SENIOR NOTES DUE 2034

Ovia Health Expands Women's Health Offerings with Comprehensive Postpartum Experience

Labcorp to Announce Third Quarter Financial Results on October 24, 2024

Advantage Healthcare Holdings Appoints Dinak Nair as Chief Executive Officer

Dividends

Labcorp Declares Quarterly Dividend

Labcorp Expands Sexually Transmitted Infection (STI) Test Offerings with Rapid Syphilis Test

NOWDiagnostics and Labcorp Collaborate to Expand Access to the Only FDA-Marketing Authorized Over-the-Counter Syphilis Test in the U.S.

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

Labcorp Announces 2024 Third Quarter Results

Praia Health Secures Strategic Investment from Labcorp Venture Fund, Announces New Collaboration to Streamline Patient Lab Ordering Experience

AHCO

MASI

MSCI

NVCR

PODD

VRSK

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Labcorp Holdings

매도 수량

Labcorp Holdings (NYSE:LH) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌